ClinConnect ClinConnect Logo
Search / Trial NCT02687841

A Uremic Toxin Absorbent (AST-120) to Treat Hospital Acquired Acute Kidney Injury

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Feb 17, 2016

Trial Information

Current as of June 14, 2025

Unknown status

Keywords

Acute Kidney Injury Indoxylsulfate P Cresol Ast 120

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • This is a prospective randomized placebo controlled trial. All patients admitted to participating centers with newly diagnosed acute kidney injury (AKI) will be screened for eligibility. The diagnosis of AKI will be determined and staged according to the KIGO-AKI Guideline.11 The inclusion criteria include:
  • 1. Age ≥ 20 years old on the day of admission
  • 2. AKI develops during admission, as defined with KDIGO-AKI Guideline,11 namely, elevation of serum creatinine above 0.3mg/dL within two days, above 1.5times baseline.
  • Patients with the following conditions will be excluded:
  • 1. Baseline estimated glomerular filtration rates (eGFR) less than 30ml/min/1.73m2 or greater than 90ml/min/1.73m2 according to MDRD equation.
  • 2. Acute kidney injury diagnosed in the indexed admission (according to baseline creatinine)
  • 3. Ileus or under fasting status
  • 4. Previous gastrointestinal operation.
  • 5. Chronic constipation, as defined with bowel movement less than three times a day. If usage of oral laxatives can achieve bowel movement of more than 3 times a day, this patient will not be excluded.
  • 6. Patients had ever undergone any modality of renal replacement therapy (RRT)
  • 7. Patients with major hemorrhage, as defined with requirement of blood transfusion during index admission.
  • 8. Patients with a biopsy proved or clinically diagnosed liver cirrhosis, Child classification B or C.
  • 9. Patients with a congestive heart failure of NYHA Class III or IV, or requirement of inotropic agents.
  • 10. Patients with a chronic lung disease requiring non-invasive or invasive positive pressure ventilation.
  • 11. Solid organ or hematological transplantation donors.
  • 12. Patients who had been diagnosed as AKI in the index hospitalization, as defined with KDIGO 2012 criteria.
  • 13. Patients with oliguric acute kidney injury, as defined with less than 500cc/day.
  • 14. Evidence of obstructive acute kidney injury under kidney echosonography.

About National Taiwan University Hospital

National Taiwan University Hospital (NTUH) is a leading medical institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a pioneer in medical education and patient care in Taiwan, NTUH integrates cutting-edge technology with comprehensive clinical expertise to facilitate groundbreaking studies across various medical fields. The hospital’s dedicated research team collaborates with local and international partners to enhance the understanding of diseases and improve treatment outcomes. By prioritizing patient safety and ethical standards, NTUH strives to contribute to the global medical community and foster advancements in healthcare practices.

Locations

Douliou, , Taiwan

Patients applied

0 patients applied

Trial Officials

YU-SHENG WU

Principal Investigator

National Taiwan University Hospital

Tao-Min Huang

Principal Investigator

National Taiwan University Hospital, Yun-Lin Branch

Wei-Shun Yang

Principal Investigator

National Taiwan University Hospital Hsin-Chu Branch

JUI-HSIANG LIN

Principal Investigator

Taoyuan General Hospital

Ya-Fei Yang

Principal Investigator

China Medical University Hospital

Chan-Yu Lin

Principal Investigator

Chang Gung Memorial Hospital

Heng-Chih Pan

Principal Investigator

Chang Gung Memorial Hospital

Chih-Chin Kao

Principal Investigator

Taipei Medical University Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials